jCyte-Santen deal positions CIRM-funded stem cell therapy for pivotal studies, global access

By Elizabeth S. Eaton, Staff Writer | May 9, 2020 | 1:31 AM GMT

Cash from an ex-U.S. licensing deal with Santen, plus years of grants from CIRM, position jCyte to bring its genetic blindness stem cell therapy into pivotal studies.

Santen Pharmaceutical Co. Ltd. (Tokyo:4536) will receive exclusive rights to jCell

Read the full 379 word article

How to gain access

Continue reading with a
two-week free trial.